HALO logo
halo search icon
Gain Therapeutics, Inc.
Gain Therapeutics, Inc.
GANX · NAS

Gain Therapeutics, Inc.

US$1.65

Price Arrow0.06 (3.77%)
20/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusBig CandleHALO AllHALO Consensus ValueHALO Earnings Momentum
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Gain Therapeutics, Inc. Overview

GANX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Neutral

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About GANX

icon

Website

Gain Therapeutics, Inc.

icon

Telephone

1.301.500.1556

icon

Address

Suite 220, 4800 Montgomery Lane, Bethesda, MD 20814

Description

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

GANX Price Chart

Key Stats

Market Cap

US$67.82M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 1.41 - 4.34

Trade Value (12mth)

US$467,391.00

1 week

-9.14%

1 month

-23.92%

YTD

-50%

1 year

-12.15%

All time high

17.93

Key Fundamentals

EPS 3 yr Growth

-58.70%

EBITDA Margin

0.00%

Operating Cashflow

-$18m

Free Cash Flow Return

-137.80%

ROIC

-150.50%

Interest Coverage

0.00

Quick Ratio

6.60

Other Data

Shares Outstanding (Fully Diluted)

42m

HALO Sector

Healthcare

Next Company Report Date

01-Apr-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

GANX Announcements

Latest Announcements

DateAnnouncements
12 May 26
12 May 26
12 May 26
12 May 26
08 April 26

GANX Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-1.71-0.89-0.61locklocklock
EPS (Fully Diluted)
$locklocklocklock-1.71-0.89-0.61locklocklock
Growth
%locklocklocklock-15.647.931.4locklocklock
PE
XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Gain Therapeutics, Inc. (GANX:NAS)?
Halo FAQ
The current share price of Gain Therapeutics, Inc. (GANX:NAS) is USD$1.65.
What is the 52-week high share price for Gain Therapeutics, Inc. (GANX:NAS)?
Halo FAQ
The 52-week high share price for Gain Therapeutics, Inc. (GANX:NAS) is USD$4.34.
What is the 52-week low share price for Gain Therapeutics, Inc. (GANX:NAS)?
Halo FAQ
The 52-week low share price for Gain Therapeutics, Inc. (GANX:NAS) is USD$1.41.
What is the dividend yield for Gain Therapeutics, Inc. (GANX:NAS)?
Halo FAQ
Gain Therapeutics, Inc. (GANX:NAS) does not pay a dividend.
What was Gain Therapeutics, Inc. (GANX:NAS) last dividend payment?
Halo FAQ
Gain Therapeutics, Inc. (GANX:NAS) does not pay a dividend.
What is the franking level for Gain Therapeutics, Inc. (GANX:NAS)?
Halo FAQ
Gain Therapeutics, Inc. (GANX:NAS) has a franking level of 0.00%.
In which sector is Gain Therapeutics, Inc. (GANX:NAS) classified?
Halo FAQ
Gain Therapeutics, Inc. (GANX:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.